c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas

Shigeo Oba, Yasuhiro Yamada, Kazuhiro Murayama, Eriel Sandika, Hikaru Sasaki, Seiji Yamada, Masato Abe, Mitsuhiro Hasegawa, Yuichi Hirose

Research output: Contribution to journalArticle

Abstract

Objective: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. Methods: A total of 153 patients with histologically defined World Health Organization grade II–IV diffuse astrocytic and oligodendroglial tumors were analyzed. Results: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. Conclusions: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.

Original languageEnglish
Pages (from-to)e1042-e1049
JournalWorld Neurosurgery
Volume126
DOIs
Publication statusPublished - 01-06-2019

Fingerprint

Astrocytoma
Glioblastoma
Glioma
Oligodendroglioma
Neoplasms
Survival
Disease-Free Survival
Growth

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Oba, Shigeo ; Yamada, Yasuhiro ; Murayama, Kazuhiro ; Sandika, Eriel ; Sasaki, Hikaru ; Yamada, Seiji ; Abe, Masato ; Hasegawa, Mitsuhiro ; Hirose, Yuichi. / c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. In: World Neurosurgery. 2019 ; Vol. 126. pp. e1042-e1049.
@article{ef5c3758d80e4f64bc1bc59717affe57,
title = "c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas",
abstract = "Objective: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. Methods: A total of 153 patients with histologically defined World Health Organization grade II–IV diffuse astrocytic and oligodendroglial tumors were analyzed. Results: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3{\%}; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4{\%}; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6{\%}; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20{\%}; glioblastoma, IDH-mutant: 2, 100{\%}, DA, IDH-wildtype: 9 cases, 33.3{\%}; AA, IDH-wildtype: 20 cases, 30.0{\%}; and glioblastoma, IDH-wildtype: 59 cases, 52.5{\%}. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. Conclusions: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.",
author = "Shigeo Oba and Yasuhiro Yamada and Kazuhiro Murayama and Eriel Sandika and Hikaru Sasaki and Seiji Yamada and Masato Abe and Mitsuhiro Hasegawa and Yuichi Hirose",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.wneu.2019.03.040",
language = "English",
volume = "126",
pages = "e1042--e1049",
journal = "World Neurosurgery",
issn = "1878-8750",
publisher = "Elsevier Inc.",

}

c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas. / Oba, Shigeo; Yamada, Yasuhiro; Murayama, Kazuhiro; Sandika, Eriel; Sasaki, Hikaru; Yamada, Seiji; Abe, Masato; Hasegawa, Mitsuhiro; Hirose, Yuichi.

In: World Neurosurgery, Vol. 126, 01.06.2019, p. e1042-e1049.

Research output: Contribution to journalArticle

TY - JOUR

T1 - c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas

AU - Oba, Shigeo

AU - Yamada, Yasuhiro

AU - Murayama, Kazuhiro

AU - Sandika, Eriel

AU - Sasaki, Hikaru

AU - Yamada, Seiji

AU - Abe, Masato

AU - Hasegawa, Mitsuhiro

AU - Hirose, Yuichi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Objective: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. Methods: A total of 153 patients with histologically defined World Health Organization grade II–IV diffuse astrocytic and oligodendroglial tumors were analyzed. Results: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. Conclusions: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.

AB - Objective: c-Met has been shown to be associated with tumor growth in several human cancers. This study aims to evaluate the correlation between the c-Met expression and histopathologic/clinical characteristics. Methods: A total of 153 patients with histologically defined World Health Organization grade II–IV diffuse astrocytic and oligodendroglial tumors were analyzed. Results: For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. Furthermore, it was correlated with overall survival in AO, oligodendroglial tumors, DA, IDH-mutant, DA, IDH-wildtype, and glioblastoma, IDH-wildtype, and tend to be correlated with overall survival in IDH-mutant lower-grade astrocytic tumors. Conclusions: c-Met expression was revealed to be a useful marker for prognosis prediction in IDH-mutant lower-grade gliomas and glioblastoma, IDH-wildtype, representing a new independent prognostic marker that can be easily measured.

UR - http://www.scopus.com/inward/record.url?scp=85064248430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064248430&partnerID=8YFLogxK

U2 - 10.1016/j.wneu.2019.03.040

DO - 10.1016/j.wneu.2019.03.040

M3 - Article

VL - 126

SP - e1042-e1049

JO - World Neurosurgery

JF - World Neurosurgery

SN - 1878-8750

ER -